Elizabeth R. Plimack, MD, of Fox Chase Cancer Center, discusses highlights of three important abstracts on advanced and metastatic urothelial cancer presented at the 2017 ASCO Annual Meeting. (Abstracts 4501, 4503, 106)
Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and Clifford A. Hudis, MD, ASCO’s current CEO, discuss the state of cancer care and the challenges that lie ahead.
Jane McNeil Beith, MD, PhD, of Chris O’Brien Lifehouse, discusses long-term study results on a psychological intervention, called “Conquer Fear,” designed to reduce clinical levels of fear of cancer recurrence in breast, colorectal, and melanoma cancer survivors. (Abstract LBA10000)
Eric Jonasch, MD, of The University of Texas MD Anderson Cancer Center, discusses the largest prospective VHL disease-specific therapeutic trial performed to date, and the data that show pazopanib resulted in significant and sustained disease control for the majority of patients enrolled on the study. (Abstract 4516)
Arnaud Scherpereel, MD, PhD, of the University Hospital of Lille, discusses phase II study findings on second- or third-line nivolumab vs nivolumab plus ipilimumab in malignant pleural mesothelioma patients. (Abstract LBA8507)
Ronald J. Buckanovich, MD, PhD, of the University of Michigan, discusses study findings on chemotherapy and cediranib in relapsed ovarian cancer. (Abstract 5506)
